Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polynovo ( (AU:PNV) ) just unveiled an announcement.
Polynovo Limited has announced a change in the director’s interest, with David Williams acquiring an additional 50,030 ordinary shares through an on-market trade, increasing his total holdings to 21,600,000 shares. This acquisition, valued at $75,045, reflects continued confidence in the company’s prospects and could potentially influence investor perception positively.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
Polynovo Limited operates in the medical technology industry, focusing on the development and commercialization of innovative medical devices. The company is primarily known for its NovoSorb technology, which is used in tissue regeneration and wound care.
YTD Price Performance: -29.41%
Average Trading Volume: 2,705,969
Technical Sentiment Signal: Sell
Current Market Cap: A$994.8M
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.